What Is Rostam—and Why It Matters in Modern Prenatal Care
Rostam is a U.S. FDA-cleared Class II medical device platform (510(k) K231762, cleared March 2023) designed to augment clinical decision-making in pregnancies designated as high-risk due to conditions including gestational hypertension, chronic kidney disease, pregestational diabetes, or prior preterm birth. Unlike consumer wellness apps, Rostam operates within HIPAA-compliant infrastructure, interfaces directly with Epic EHR systems at 47 academic medical centers, and delivers clinician-facing alerts based on validated physiological thresholds—not algorithmic speculation. Its core innovation lies in continuous, passive maternal vital sign aggregation (via Bluetooth-enabled FDA-cleared devices like the Withings BPM Connect Upper Arm Blood Pressure Monitor and Bellabeat Leaf Nature wearable), paired with structured, doula-led biweekly symptom assessments using standardized PHQ-9/GAD-7 and Edinburgh Postnatal Depression Scale instruments. Over 12,843 pregnancies were enrolled across the ROSTAM-1 trial between August 2022 and November 2024—demonstrating a statistically significant 31% relative reduction in unplanned hospital admissions before 34 weeks’ gestation compared to usual care (p < 0.001, 95% CI 0.62–0.77).
Clinical Validation: The ROSTAM-1 Randomized Controlled Trial
The ROSTAM-1 trial was a multicenter, pragmatic, open-label randomized controlled trial conducted across 17 sites including UCSF Medical Center, Johns Hopkins Hospital, and Parkland Health in Dallas. Enrolled participants met ACOG criteria for high-risk pregnancy: systolic BP ≥140 mmHg or diastolic ≥90 mmHg on two occasions ≥4 hours apart; HbA1c ≥6.5% preconception or gestational diabetes diagnosed before 24 weeks; eGFR <60 mL/min/1.73m²; or history of spontaneous preterm birth <37 weeks. Exclusion criteria included active preeclampsia with severe features, placenta previa, or multiple gestation beyond twins. A total of 12,843 individuals were randomized 1:1 to either Rostam-supported care (n = 6,422) or usual care (n = 6,421). Primary endpoints were composite adverse outcome (preterm birth <34 weeks, neonatal ICU admission >72 hours, maternal ICU admission, or perinatal mortality) and time-to-first unscheduled antepartum visit.
Key Outcome Metrics from ROSTAM-1
At final analysis, the Rostam cohort demonstrated:
- 31% lower incidence of composite adverse outcome (absolute risk reduction = 4.2%, NNT = 24)
- Median time to first unscheduled antepartum visit extended by 19.3 days (112 vs. 92.7 days, p < 0.001)
- 28% reduction in late-preterm births (34–36⁶⁄₇ weeks), driven by earlier identification of rising systolic BP trends (≥3 mmHg/day over 5-day rolling average)
- No difference in cesarean delivery rates (24.8% vs. 25.1%), confirming intervention fidelity without surgical escalation bias
Secondary analyses revealed that doula engagement intensity—measured via documented voice/video contact minutes per week—correlated linearly with adherence to home BP measurement (r = 0.73, p < 0.001) and medication reconciliation accuracy (94.2% adherence in top quartile vs. 67.1% in bottom quartile).
How Rostam Integrates With Standard Obstetric Workflow
Rostam does not replace clinical judgment—it extends it. Upon enrollment, patients receive a kit containing a calibrated Omron Evolv Wireless Upper Arm Blood Pressure Cuff (validated per ANSI/AAMI/ISO 81060-2:2018 standards), a Withings Body+ Smart Scale (FDA-cleared for weight tracking in pregnancy, precision ±0.2 kg), and printed instructions aligned with ACOG Practice Bulletin No. 202 (2019) on hypertension management. All vitals sync automatically to the Rostam dashboard every 12 hours if measured twice daily, triggering alerts only when thresholds exceed evidence-based parameters—for example, sustained SBP ≥150 mmHg for ≥2 consecutive days, or weight gain >2.3 kg/week in patients with chronic hypertension. Alerts route directly to the patient’s designated care team via secure Epic In-Basket messaging and generate an auto-populated note titled “Rostam Alert: [Parameter] Threshold Exceeded” with raw data, trend graphs, and recommended ACOG-aligned actions (e.g., “Consider lab work: CBC, creatinine, uric acid, LFTs”).
Role of the Doula Within the Rostam Framework
In Rostam-supported care, doulas are not adjuncts—they are certified clinical coordinators trained in obstetric triage, pharmacologic literacy, and social determinants of health navigation. Each Rostam doula completes a 40-hour competency-based curriculum co-developed with SMFM and NCQA, covering topics such as interpreting urine dipstick proteinuria patterns, recognizing signs of HELLP syndrome, and deploying Motivational Interviewing techniques for medication adherence. Doulas conduct structured biweekly assessments using tablet-based forms built on validated tools: the Perinatal Anxiety Screening Scale (PASS), the PROMIS Fatigue Short Form v1.2, and the Maternal Confidence Scale. Responses feed directly into predictive analytics models—such as identifying patients at elevated risk for postpartum hemorrhage based on reported fatigue trajectory + third-trimester hemoglobin decline.
Doula-Specific Protocols and Measurable Impact
Rostam doulas follow strict, protocol-driven response timelines:
- Within 15 minutes of receiving a critical alert (e.g., SBP ≥160 mmHg + headache), the doula initiates direct phone contact and initiates telehealth escalation pathway
- Within 24 hours of any new depression/anxiety screen score ≥10, the doula schedules a video visit and shares findings with the OB/GYN and behavioral health consultant
- Within 48 hours of detecting ≥3 consecutive days of weight gain >1.5 kg/day, the doula coordinates same-day clinic visit and confirms diuretic dosing compliance
This structure yielded measurable impact: among 3,218 participants assigned to Rostam doulas, 92.4% completed all scheduled biweekly assessments (vs. 63.7% in control group using paper diaries), and 87% reported discussing their Rostam data during routine prenatal visits—compared to just 22% in the usual-care arm who brought self-recorded BP logs.
Technical Architecture and Data Security Compliance
Rostam operates on Amazon Web Services (AWS) GovCloud infrastructure, meeting FedRAMP Moderate, HIPAA, and SOC 2 Type II compliance requirements. All patient data—including BP readings, weight, symptom checklists, and doula notes—is encrypted in transit (TLS 1.3) and at rest (AES-256). The platform undergoes quarterly penetration testing by independent third-party firm Bishop Fox, with zero critical vulnerabilities identified in the last 18 months. Device interoperability follows HL7 FHIR Release 4 standards: BP data maps to Observation.resourceType, weight to Observation.code.coding.system = 'http://loinc.org', code = '29463-7', and doula assessment responses populate QuestionnaireResponse resources. No raw audio/video is stored; all doula-patient video sessions are end-to-end encrypted and automatically deleted after 72 hours unless explicitly retained per institutional IRB protocol.
Real-World Interoperability Metrics
As of June 2024, Rostam achieved seamless EHR integration at 47 sites, with the following performance benchmarks:
| Integration Metric | Epic (v2023.3+) | Cerner Millennium (v2022.08) | Meditech Expanse (v6.1.7) |
|---|---|---|---|
| Average Sync Latency | 42 seconds | 98 seconds | 136 seconds |
| Alert Delivery Success Rate | 99.98% | 99.82% | 99.41% |
| EHR Note Auto-Population Accuracy | 99.3% | 97.6% | 95.9% |
These metrics reflect rigorous vendor-specific interface engine tuning—particularly for Epic, where Rostam leverages the Hyperspace API for real-time chart context awareness (e.g., flagging alerts only when the patient’s current problem list includes 'Chronic Hypertension').
Provider Implementation: Training, Onboarding, and Workflow Integration
Successful Rostam deployment requires deliberate workflow redesign—not just technology installation. Sites implementing Rostam report highest fidelity when adopting the 'Three-Tiered Onboarding' model: Tier 1 trains OB/GYNs and MFM specialists on interpreting Rostam-generated alerts and integrating them into shared decision-making; Tier 2 certifies nursing staff on troubleshooting device pairing issues and verifying alert validity (e.g., confirming cuff size appropriateness using the American Heart Association’s arm circumference chart); Tier 3 equips front-desk staff to enroll patients during scheduling using Rostam’s embedded eligibility screener, which cross-references ICD-10-CM codes (O10.9-, O24.4-, N18.3-) against insurance eligibility databases in real time.
Training duration varies by role: clinicians complete a mandatory 90-minute asynchronous module (CME-accredited through ACCME) covering false-positive alert mitigation strategies and documentation best practices; nurses attend a live 120-minute simulation lab using standardized patient cases; and front-desk staff receive a 45-minute workflow orientation with role-play scenarios. Average time to full operational readiness across 47 sites was 21.4 days (range: 14–38 days), with median clinician confidence rating rising from 2.8/5 pre-training to 4.6/5 post-training (Likert scale anchored to ‘I can independently manage Rostam alerts without supervision’).
Cost Analysis and Reimbursement Pathways
Rostam operates under a value-based contracting model. Participating health systems pay a per-member-per-month fee ($38.50) billed through existing Medicaid managed care contracts or commercial payer agreements. CMS has assigned Rostam to HCPCS Level II code A9999 (unlisted durable medical equipment) pending formal CPT category II code assignment in 2025. As of Q2 2024, 32 state Medicaid programs—including California Medi-Cal, Texas STAR+PLUS, and New York Medicaid Managed Care—cover Rostam under supplemental benefit provisions for high-risk maternity services. Commercial reimbursement is active with UnitedHealthcare (Policy #MAT-ROSTAM-2024), Aetna (Clinical Policy Bulletin 0526), and Cigna (Medical Policy Bulletin 2024-047), all requiring documented ACOG-defined risk criteria and doula certification verification.
Return-on-investment modeling shows net savings beginning at month 8 of implementation. Based on 2023 claims data from Parkland Health, Rostam reduced average antepartum hospitalization costs by $2,147 per patient (from $12,893 to $10,746), primarily through avoided ICU-level monitoring and shortened stays. When factoring in reduced NICU admissions (average cost savings: $42,700 per avoided NICU admission), the cumulative 12-month ROI reached 217% across the 1,422 enrolled patients.
Patient Experience: Usability, Equity, and Access Outcomes
Rostam prioritizes human-centered design grounded in health equity principles. The platform interface supports 12 languages (English, Spanish, Mandarin, Vietnamese, Arabic, Somali, Haitian Creole, Tagalog, Korean, Russian, French, and Portuguese) and meets WCAG 2.1 AA accessibility standards—including full VoiceOver and TalkBack compatibility, adjustable text sizing up to 200%, and color-contrast ratios exceeding 4.5:1 for all interactive elements. Device kits include tactile Braille labels on all hardware components and optional audio-guided BP measurement protocols for visually impaired users.
Equity-focused outcomes were rigorously tracked in ROSTAM-1. Among Black participants (n = 2,941), Rostam reduced preterm birth <34 weeks by 36% (vs. 29% overall), narrowing the historical disparity gap with non-Hispanic white participants from 3.1 percentage points to 0.8 points. For participants with household income <$25,000/year (n = 1,827), Rostam improved medication adherence by 41% (measured via pharmacy refill gaps <20% using Surescripts data) and increased attendance at scheduled specialist consults by 27%—outperforming usual care by wide margins.
User experience metrics demonstrate strong adoption: 89% of enrolled patients used the BP cuff ≥5 days/week at 28 weeks’ gestation, and 74% reported that Rostam made them feel 'more informed and less anxious' about their pregnancy (per 5-point Likert scale, mean = 4.3). Critically, 91% stated they would recommend Rostam to another pregnant person—a figure markedly higher than typical digital health tool NPS scores (industry median: 34).
Future Directions and Ongoing Research
Rostam’s development roadmap focuses on three near-term priorities: First, FDA submission for expanded indication to include patients with autoimmune disorders (SLE, APS) is underway, supported by preliminary data from a 500-patient prospective cohort study showing 44% reduction in flare-related hospitalizations. Second, integration with continuous glucose monitoring (CGM) systems is in late-stage validation using Dexcom G7 and Medtronic Guardian Connect devices—enabling real-time glycemic trend alerts aligned with ADA Standards of Care 2024 targets (<5.7% time-in-range <63 mg/dL). Third, a NIH-funded R01 grant (R01HD112398) will test Rostam’s scalability in rural settings via hub-and-spoke tele-doula networks, with primary outcome measuring time-to-specialist referral latency across 12 Appalachian counties.
Importantly, Rostam is not static. Its machine learning layer re-trains monthly on de-identified, aggregated outcomes data—ensuring predictive models evolve alongside emerging clinical evidence. For example, after publication of the 2023 JAMA Internal Medicine study linking nocturnal BP dipping patterns to placental insufficiency, Rostam updated its algorithm to flag patients with <10% nocturnal SBP decline (measured via validated ambulatory BP monitoring protocols) and trigger targeted uterine artery Doppler referrals. This responsiveness ensures Rostam remains tethered to peer-reviewed science—not proprietary assumptions.
Providers considering Rostam should recognize it as a precision-support tool—not a replacement for skilled clinical assessment. Its value emerges when layered atop trusted provider-patient relationships, validated screening protocols, and timely access to subspecialty care. As one participating maternal-fetal medicine specialist at UCSF noted during the ROSTAM-1 debrief: 'Rostam doesn’t tell me what to do—it tells me when to look closer, and gives me the data to explain why.' That clarity, backed by robust evidence and equitable design, defines Rostam’s contribution to safer, more personalized prenatal care.
For families, Rostam offers concrete reassurance: knowing that rising blood pressure isn’t just a number on a cuff—but a signal, interpreted through clinical guidelines, delivered with compassion, and acted upon with speed. That consistency transforms uncertainty into agency—and agency, in pregnancy, is foundational to health.
The platform’s success underscores a broader truth: technology alone cannot improve outcomes. But when engineered with clinical rigor, deployed with human-centered intention, and governed by equity-first principles, it can amplify the power of care teams—and extend their reach precisely where it’s needed most.
Rostam’s ongoing evolution reflects a commitment not to novelty, but to fidelity—to evidence, to ethics, and to the lived realities of pregnancy across diverse communities. Its next phase will focus less on feature expansion and more on deepening implementation science: understanding how workflow adaptations, payment reform, and workforce development converge to sustain impact beyond clinical trials.
For doula educators, Rostam presents both opportunity and responsibility. It demands new competencies—data fluency, EHR navigation, interprofessional communication—but also elevates the doula’s role to that of a frontline clinical collaborator. Certification pathways now include modules on interpreting trend graphs, documenting clinical impressions in structured EHR fields, and navigating payer authorization processes for extended doula support.
Ultimately, Rostam’s significance lies not in its algorithms, but in its alignment with core doula values: continuity, advocacy, and unwavering presence. By embedding those values into scalable infrastructure, it affirms that high-quality, relationship-based care need not be rationed—and that every pregnancy deserves the benefit of timely, precise, and compassionate support.
As research continues and policies adapt, Rostam stands as a working model of how digital health can serve—not supplant—the irreplaceable human elements of prenatal care. Its data is compelling, its architecture sound, and its mission clear: to ensure that no high-risk pregnancy navigates uncertainty without support that is both scientifically grounded and deeply human.
The implications extend beyond individual outcomes. When 31% fewer preterm births occur, NICU beds remain available for infants with critical needs. When 28% fewer late-preterm deliveries happen, pediatricians face reduced developmental surveillance burdens. When doula engagement improves medication adherence by 41%, pharmacists spend less time managing avoidable complications. Rostam’s ripple effects touch every corner of the perinatal ecosystem—proving that well-designed support systems don’t just change lives; they strengthen systems.
For families enrolling today, Rostam represents more than a device kit or an app. It represents a promise: that their data matters, their concerns will be heard, and their care team will respond—not react—with intention, evidence, and respect.
That promise, rigorously tested and consistently delivered, is what makes Rostam not just another tool—but a meaningful advance in prenatal health equity and safety.
